💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Loratadine

CHEMBL998 Phase 4 Approved Small molecule
Half-Life
8 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
382.9 g/mol
LogP
5.2
Phase
4

A second-generation, non-sedating antihistamine used to relieve allergic rhinitis and hives (urticaria). It blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness.

Molecular Weight

382.8800 g/mol

LogP

5.20

TPSA

42.40 Ų

Lipinski RO5

Pass

Therapeutic Areas

Asthma Atopic Dermatitis Breast Cancer Chronic Kidney Disease Leukemia Lymphoma Multiple Sclerosis Parkinson's Disease Psoriasis Rheumatoid Arthritis

Drug Classes

R — R - Respiratory System

Mechanism of Action

Second-generation H1 antihistamine with minimal CNS effects.

Pharmacokinetics (PK)

Half-Life 8 hours

Pharmacodynamics (PD)

Mechanism

Second-generation H1 antihistamine with minimal CNS effects.

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1

                

                

                
                

                    
InChI

                    
InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H23ClN2O2

                    

                    
                    

                        
HBD / HBA

                        
- / 3

                    

                    
                    

                        
Rotatable Bonds

                        
2

                    

                    
                    
                    

                        
Heavy Atoms

                        
27

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            HRH1 (Histamine H1 Receptor)
                            Antagonist
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Loratadine + Azithromycin
                            
                        

                        
                        
Azithromycin is a weak CYP3A4 inhibitor that can modestly raise loratadine plasma levels; the clinical impact is minimal given loratadine's wide therapeutic index and low cardiac risk.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Loratadine + Fluconazole
                            
                        

                        
                        
Fluconazole inhibits CYP3A4-mediated metabolism of loratadine, modestly increasing loratadine plasma concentrations; however, loratadine's poor CNS penetration limits the clinical consequence.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
A second-generation, non-sedating antihistamine used to relieve allergic rhinitis and hives (urticaria). It blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Second-generation H1 antihistamine with minimal CNS effects.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Loratadine: Half-life: 8 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Loratadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Albuterol
                            Small molecule
                        
                        
                        
                            Cetirizine
                            Small molecule
                        
                        
                        
                            Diphenhydramine
                            Small molecule
                        
                        
                        
                            Montelukast
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL998.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3957.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.